Antag Therapeutics ApS
CVR number: 38402056
Ole Maaløes Vej 3, 2200 København N
antag@antagtherapeutics.com
tel: 21456537
http://www.antagtherapeutics.com/
Income statement (kDKK)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | -7 866.66 | -10 925.24 | -13 826.24 | -9 904.46 | -13 707.57 |
| Employee benefit expenses | -3 492.52 | -3 692.93 | -1 912.09 | -1 501.61 | -2 291.35 |
| Total depreciation | -12.99 | -26.62 | -33.77 | -33.77 | -33.12 |
| EBIT | -11 372.17 | -14 644.80 | -15 772.09 | -11 439.84 | -16 032.03 |
| Other financial income | 0.13 | 1 503.79 | 31.32 | 22.64 | 58.99 |
| Other financial expenses | - 463.97 | -1 831.76 | -1 717.93 | - 580.17 | - 998.01 |
| Pre-tax profit | -11 836.01 | -14 972.78 | -17 458.70 | -11 997.37 | -16 971.05 |
| Income taxes | 2 603.82 | 2 619.46 | 2 595.36 | 2 213.01 | 3 159.66 |
| Net earnings | -9 232.19 | -12 353.32 | -14 863.34 | -9 784.35 | -13 811.39 |
Assets (kDKK)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Machinery and equipment | 116.88 | 113.64 | 79.87 | 46.10 | 12.99 |
| Tangible assets total | 116.88 | 113.64 | 79.87 | 46.10 | 12.99 |
| Other receivables | 16.76 | ||||
| Investments total | 16.76 | ||||
| Long term receivables total | |||||
| Inventories total | |||||
| Prepayments and accrued income | 13.99 | 20.22 | 37.70 | 3.72 | 3.13 |
| Current other receivables | 907.27 | 417.60 | 2 305.11 | 1 371.50 | |
| Current deferred tax assets | 2 603.82 | 2 987.64 | 2 595.36 | 2 213.01 | 3 159.66 |
| Short term receivables total | 3 525.07 | 3 007.86 | 3 050.66 | 4 521.84 | 4 534.28 |
| Cash and bank deposits | 10 473.76 | 12 599.55 | 17 540.56 | 12 995.80 | 19 406.30 |
| Cash and cash equivalents | 10 473.76 | 12 599.55 | 17 540.56 | 12 995.80 | 19 406.30 |
| Balance sheet total (assets) | 14 115.71 | 15 721.05 | 20 671.09 | 17 563.74 | 23 970.33 |
Equity and liabilities (kDKK)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Share capital | 76.06 | 76.06 | 130.64 | 135.30 | 135.30 |
| Retained earnings | 11 740.33 | 2 508.14 | 25 590.30 | 14 287.86 | 4 503.50 |
| Profit of the financial year | -9 232.19 | -12 353.32 | -14 863.34 | -9 784.35 | -13 811.39 |
| Shareholders equity total | 2 584.20 | -9 769.12 | 10 857.60 | 4 638.80 | -9 172.59 |
| Provisions | 12 924.94 | 3 127.74 | |||
| Non-current loans from credit institutions | 10 652.14 | 24 530.11 | 8 670.58 | 9 106.24 | 28 276.33 |
| Non-current other liabilities | 96.62 | 147.27 | |||
| Non-current liabilities total | 10 748.75 | 24 677.38 | 8 670.58 | 9 106.24 | 28 276.33 |
| Current loans from credit institutions | 1 738.85 | ||||
| Current trade creditors | 491.22 | 590.00 | 501.94 | 1 409.85 | 2 467.85 |
| Other non-interest bearing current liabilities | 291.54 | 222.79 | 640.97 | 2 408.85 | -2 467.85 |
| Current liabilities total | 782.76 | 812.79 | 1 142.91 | 3 818.70 | 1 738.85 |
| Balance sheet total (liabilities) | 14 115.71 | 15 721.05 | 20 671.09 | 30 488.69 | 23 970.33 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.